Get the Stockscreener App
0.86
4.97%
-0.045
Inflarx N V stock is traded at $0.86, with a volume of 123.61K.
It is down -4.97% in the last 24 hours and up +7.50% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$0.905
Open:
$0.905
24h Volume:
123.61K
Relative Volume:
0.26
Market Cap:
$57.73M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-0.9951
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
-4.31%
1M Performance:
+7.50%
6M Performance:
-64.32%
1Y Performance:
-43.42%
1-Day Range:
$0.836
$0.91
1-Week Range:
$0.836
$0.95
52-Week Range:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.86 | 61.31M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
InflaRx (IFRX) to Release Earnings on Thursday - Defense World
Why InflaRx N.V. stock attracts strong analyst attentionGrowth Projection Summary for Long-Term Investors - Newser
How volatile is InflaRx N.V. stock compared to the marketBeginner Investor Report With Low Risk - jammulinksnews.com
What to do if you’re stuck in InflaRx N.V.Sector Rotation and Stock Opportunity Analysis - Newser
Sentiment Turns Positive on InflaRx N.V. — Reversal AheadLong Hold Safe Return Strategy Reviewed - metal.it
Tools to assess InflaRx N.V.’s risk profileTechnical Entry Plan with Risk Minimization - Newser
InflaRx N.V. stock momentum explainedFree Low Risk Buy Zone Opportunity Watch - Newser
Does InflaRx N.V. stock perform well during market downturnsReal Time Tracker With High Returns - jammulinksnews.com
How does InflaRx N.V. compare to its industry peersValue Investing Recommendation For Every Investor - jammulinksnews.com
InflaRx receives Nasdaq notice for non-compliance with minimum bid price rule - MSN
InflaRx (NASDAQ:IFRX) Trading 2.8% Higher – What’s Next? - Defense World
Applying Elliott Wave Theory to InflaRx N.V.Equity Portfolio Outlook and Performance Summary - Newser
InflaRx to Report Second Quarter 2025 Results on August 7, - GlobeNewswire
InflaRx Q2 Earnings Coming August 7: Anti-Inflammatory Drug Developer's Latest Financial Picture - Stock Titan
What MACD signals say about InflaRx N.V.Low Exposure Strategy with Sector Analysis - Newser
Top Risks to Consider Before Buying InflaRx N.V. Stock7-Day Equity Return Range Forecast Model - Newser
Key resistance and support levels for InflaRx N.V.Free Fundamental Winners With Safe Entry Plan - Newser
Should I hold or sell InflaRx N.V. stock in 2025Market Forecast Planner To Watch Now - jammulinksnews.com
What makes InflaRx N.V. stock price move sharplyBreakout Stock Opportunities with Low Drawdown - Newser
Is InflaRx N.V. Stock a Good Fit for Conservative InvestorsFree Stable Entry High Return Opportunities - Newser
How many analysts rate InflaRx N.V. as a “Buy”Post Market Outlook For Every Investor - jammulinksnews.com
How strong is InflaRx N.V. company’s balance sheetPhenomenal returns - jammulinksnews.com
What are analysts’ price targets for InflaRx N.V. in the next 12 monthsFree Stock Recommendation From AI Tools - jammulinksnews.com
What is the dividend policy of InflaRx N.V. stockInvest smarter with actionable market insights - jammulinksnews.com
Published on: 2025-07-27 22:45:33 - jammulinksnews.com
Is InflaRx N.V. stock overvalued or undervaluedMaster the art of timing market moves - jammulinksnews.com
Published on: 2025-07-27 21:09:30 - jammulinksnews.com
Has InflaRx N.V. Stock Ever Crashed Historical Volatility ReviewFree Stock Market Practical Discussion Forums - Newser
Is InflaRx N.V. a good long term investmentFree Consultation - PrintWeekIndia
What drives InflaRx N.V. stock priceExceptional profit potential - PrintWeekIndia
InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected - Insider Monkey
InflaRx N.V. Stock Analysis and ForecastConsistent triple returns - PrintWeekIndia
What analysts say about InflaRx N.V. stockRapid growth trajectories - PrintWeekIndia
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):